Mirum Pharmaceuticals reported that a Phase 3 trial of its chronic hepatitis delta virus therapy candidate hit its primary endpoint. The result advances Mirum’s effort to compete in a space that has been dominated by Gilead’s treatments. The company framed the approach as a commercially differentiated challenger as it seeks to broaden the therapeutic options for hepatitis delta patients. A Phase 3 primary-endpoint win is a key inflection point that can determine the timing of regulatory submissions and the competitive landscape in hepatology.